Stock Screener App

Frei -

Installieren

66.26

1.88% 1.22

after-market

Handel nachbörslich: 66.26

Cytokinetics Inc (CYTK)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt CYTK? Forum Prognose Aktiensplit

Cytokinetics Inc Aktie (CYTK) Neueste Nachrichten

CYTOKINETICS INC (NASDAQ:CYTK) Shows Strong Technicals and High-Quality Breakout Setup - ChartMill

Will Cytokinetics Incorporated stock outperform Nasdaq index2025 Macro Impact & AI Driven Price Forecasts - mfd.ru

Cytokinetics (CYTK) Valuation Check After MYQORZO Approval And Renewed Analyst Bullishness - Yahoo Finance

Cytokinetics to Announce Fourth Quarter Results on February 24, 2026 - Bitget

Cytokinetics (CYTK) Is Up 5.2% After Aficamten Milestones And Probe News Has The Bull Case Changed? - Yahoo Finance

Cytokinetics, Incorporated (NASDAQ: CYTK) Long Term Investor Alert: Investigation of potential Wrongdoing - openPR.com

Analysts Are Bullish on Top Healthcare Stocks: Cytokinetics (CYTK), Boston Scientific (BSX) - The Globe and Mail

Cytokinetics announces recipients of its eighth annual communications grant program - marketscreener.com

Cytokinetics Announces Recipients Of Its Eighth Annual Communications Grant Program - TradingView

Cytokinetics Announces Recipients of Its Eighth Annual Communications Grant Program - The Manila Times

Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire

Aug Selloffs: Is Cytokinetics Incorporated a potential multi baggerJuly 2025 Setups & Weekly High Potential Alerts - baoquankhu1.vn

Bank Watch: Does Cytokinetics Incorporated offer margin of safetyJuly 2025 Momentum & Stepwise Trade Signal Implementation - baoquankhu1.vn

Cytokinetics, Incorporated (NASDAQ:CYTK) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

Andrew Callos Sells 15,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat

Bank of America Securities Remains a Hold on Cytokinetics (CYTK) - The Globe and Mail

Surprises Report: Is Cytokinetics Incorporated stock a good pick for beginners2025 Support & Resistance & AI Enhanced Execution Alerts - baoquankhu1.vn

Cytokinetics stock maintains Buy rating at B.Riley amid strong CMI market - Investing.com Canada

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect - ACCESS Newswire

Cytokinetics, Incorporated (CYTK): A Bull Case Theory - Finviz

Truist Financial Forecasts Strong Price Appreciation for Cytokinetics (NASDAQ:CYTK) Stock - MarketBeat

Truist Raises Price Target on Cytokinetics to $92 From $84, Keeps Buy Rating - marketscreener.com

Truist Securities Raises Price Target for CYTK with Buy Rating | - GuruFocus

2026 Biotech Hot Picks: Top 7 Stocks to Watch | Truist Analysis - techi.com

Cytokinetics, Incorporated (CYTK) Stock Analysis: A Biotech Play with a 41.55% Upside Potential - DirectorsTalk Interviews

Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 886 Shares - MarketBeat

New Highs: Whats the RSI of Cytokinetics Incorporated stockQuarterly Market Review & Risk Controlled Stock Pick Alerts - baoquankhu1.vn

Lisanti Capital Growth LLC Acquires New Position in Cytokinetics, Incorporated $CYTK - MarketBeat

Universal Beteiligungs und Servicegesellschaft mbH Sells 444,464 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat

Will Cytokinetics Incorporated outperform its industry peersShort Setup & Stock Portfolio Risk Management - mfd.ru

J. Safra Sarasin Holding AG Sells 43,723 Shares of Cytokinetics, Incorporated $CYTK - MarketBeat

Cardiac Myosin Inhibitor Now Available for Treating Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy - Diagnostic and Interventional Cardiology

Halozyme buys a biotech startup; Cytokinetics launches heart drug - BioPharma Dive

Cytokinetics (CYTK) Receives Overweight Rating from Barclays, PT Set at $87 | CYTK Stock News - GuruFocus

Cytokinetics (NASDAQ:CYTK) Coverage Initiated by Analysts at Barclays - MarketBeat

Cytokinetics, Olympic Medalist McLaughlin-Levrone team up for awareness for HCM - Yahoo Finance

CYTK: Cytokinetics Launches Myqorzo in the U.S. for Heart Condition - GuruFocus

Assessing Whether Cytokinetics (CYTK) Looks Undervalued After Recent Share Price Momentum - Yahoo Finance

How MYQORZO’s REMS‑Restricted U.S. Launch Will Impact Cytokinetics (CYTK) Investors - Yahoo Finance

Truist Securities reiterates Buy rating on Cytokinetics stock at $84 target - Investing.com Canada

Cytokinetics launches first product, Myqorzo - The Pharma Letter

Analyst Upgrade: What is the long term forecast for Cytokinetics Incorporated stock2025 Price Momentum & Community Consensus Trade Signals - baoquankhu1.vn

Cytokinetics and Olympic Gold Medalist Sydney McLaughlin-Levrone Team Up to Raise Awareness of the Whole-Person Impact of Hypertrophic Cardiomyopathy (HCM) - MultiVu

Cytokinetics (CYTK) Launches HCM Awareness Campaign with Olympic Star - GuruFocus

Olympian Sydney McLaughlin-Levrone on hypertrophic cardiomyopathy at home - Stock Titan

Cytokinetics Announces U.S. Launch of MYQORZO™ (aficamten) for the Treatment of Obstructive Hypertrophic Cardiomyopathy - Quiver Quantitative

New heart drug MYQORZO reaches U.S. patients, but with strict safety rules - stocktitan.net

US FDA caps 2025 with December high of 27 drug approvals - BioWorld MedTech

Cytokinetics, Incorporated (CYTK) Stock Analysis: Uncovering a 41% Potential Upside in the Biotech Sector - DirectorsTalk Interviews

RBC Capital Maintains Cytokinetics(CYTK.US) With Buy Rating, Maintains Target Price $95 - 富途资讯

Cytokinetics Board Faces Claims of Breach of Fiduciary Duty as Stock Plummets - Intellectia AI

Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Investors to Connect - ACCESS Newswire

The Law Offices of Frank R. Cruz Announces Investigation of Cytokinetics, Incorporated (CYTK) on Behalf of Investors - marketscreener.com

Bull Bear: What are HSPOs earnings expectationsLayoff News & Capital Efficiency Focused Strategies - baoquankhu1.vn

RBC Capital Reiterates Outperform Rating for Cytokinetics (CYTK) - GuruFocus

Key facts: B. Riley Raises Cytokinetics Price Target to $108; Stock Options Issued - TradingView

Cytokinetics (CYTK) Sees Positive Analyst Rating Updates: Price Target Raised | CYTK Stock News - GuruFocus

Royal Bank Of Canada Reiterates "Outperform" Rating for Cytokinetics (NASDAQ:CYTK) - MarketBeat

Brokers Issue Forecasts for Cytokinetics FY2026 Earnings - MarketBeat

Bronstein, Gewirtz & Grossman, LLC Encourages Cytokinetics, Incorporated (CYTK) Stockholders to Inquire about Securities Investigation - ACCESS Newswire

Cytokinetics announces inducement grants under Nasdaq Listing Rule - marketscreener.com

ROIV

$26.45

1.12%

RPRX

$45.19

0.87%

INCY

$101.10

0.35%

BNTX

$105.87

0.10%

INSM

$148.75

1.77%

ONC

$346.07

0.10%

In Yahoo öffnen | In Google öffnen | In Finviz öffnen | In MarketWatch öffnen | Öffnen Sie in EDGAR | Offen in Reuters